FLORINEF

This brand name is authorized in Australia, Canada, Estonia, Finland, Hong Kong SAR China, Japan, Netherlands, New Zealand, Singapore.

Active ingredients

The drug FLORINEF contains one active pharmaceutical ingredient (API):

1	Fludrocortisone UNII V47IF0PVH4 - FLUDROCORTISONE ACETATE
	Fludrocortisone, in very small doses, maintains life in adrenalectomised animals, enhances the deposition of liver glycogen and produces thymic involution, eosinopenia, retention of sodium and increased urinary excretion of potassium.
	Read more about Fludrocortisone

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
H02AA02	Fludrocortisone	H Systemic hormonal preparations, excl. Sex hormones and insulins → H02 Corticosteroids for systemic use → H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN → H02AA Mineralocorticoids
Discover more medicines within H02AA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	1433K
CA	Health Products and Food Branch	02086026
EE	Ravimiamet	1091461, 1284409, 1706442
FI	Lääkealan turvallisuus- ja kehittämiskeskus	183871
HK	Department of Health Drug Office	00036
JP	医薬品医療機器総合機構	2452003F1035
NL	Z-Index G-Standaard, PRK	15431
NZ	Medicines and Medical Devices Safety Authority	6409
SG	Health Sciences Authority	10680P